z-logo
Premium
Seizure‐related injuries are underreported in pharmacoresistant localization‐related epilepsy
Author(s) -
Friedman David E.,
Gilliam Frank G.
Publication year - 2010
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1167.2009.02170.x
Subject(s) - epilepsy , medicine , temporal lobe , medical record , cohort , pediatrics , surgery , psychiatry
Summary Purpose:   To investigate and compare injury rates, associated risk factors, circumstances, and medical record documentation in patients with pharmacoresistant temporal lobe epilepsy (TLE) and extratemporal lobe epilepsy (ETLE). Methods:   The study cohort consisted of fifty‐two consecutive adults with treatment‐resistant epilepsy and seizure classification confirmed by video‐electrocardiography (EEG) (28 with TLE and 24 with ETLE) who consented to participate. All subjects had their seizures classified with prior video‐EEG monitoring, were followed in a tertiary‐care center in northwest New York City, and received a semistructured phone interview regarding injuries experienced since being diagnosed with epilepsy. Results:   Injuries were reported in 16 (57%) of the patients with TLE and 4 (17%) of the patients with ETLE (p = 0.004 after controlling for duration of epilepsy and seizure burden); 83% of all injuries were designated by patients as seizure‐related. Most injuries (22 of 41; 54%) were classified as moderate or greater in severity. In addition, one motor vehicle accident (MVA) was reported in the TLE group and one episode of sudden unexpected death (SUDEP) was identified in the ETLE group. More than half (55%) of the injuries were not documented as seizure‐related in medical records. Conclusion:   A substantial number of potentially serious injuries are not documented as seizure related, even in a tertiary‐care setting. Patients with pharmacoresistant TLE may be at higher risk for experiencing an injury than patients with pharmacoresistant ETLE.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here